Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Merck signs drug development deals with Moderna, Royalty Pharma

by Michael McCoy
October 15, 2022 | A version of this story appeared in Volume 100, Issue 37

 

Merck & Co. is paying and getting paid in two drug development deals. The company will pay Moderna $250 million to exercise an option to develop personalized cancer vaccines, including mRNA-4157/V940, which Moderna is evaluating in combination with Merck’s Keytruda immuno-oncology therapy in a Phase 2 trial. Separately, Royalty Pharma will pay Merck $50 million to cofund development of MK-8189, a small molecule in a Phase 2b study as a treatment for schizophrenia. Royalty buys drug royalties and also invests in late-stage drug development programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.